127 related articles for article (PubMed ID: 33630419)
1. The FDA Approves PSMAtargeted Drug for PET Imaging in Men with Prostate Cancer.
BJU Int; 2021 Mar; 127(3):267-268. PubMed ID: 33630419
[No Abstract] [Full Text] [Related]
2. FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
Masters SC; Hofling AA; Gorovets A; Marzella L
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):27-28. PubMed ID: 33857629
[No Abstract] [Full Text] [Related]
3. FDA Approves New
J Nucl Med; 2022 Feb; 63(2):26N. PubMed ID: 35101932
[No Abstract] [Full Text] [Related]
4. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
BJU Int; 2021 Aug; 128(2):127-130. PubMed ID: 34318983
[No Abstract] [Full Text] [Related]
5. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
[TBL] [Abstract][Full Text] [Related]
6. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
[TBL] [Abstract][Full Text] [Related]
7. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A
Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical use of PET/CT with
Ribeiro AMB; Lima ENP; Zequi SC
Urol Oncol; 2021 Jan; 39(1):73.e9-73.e18. PubMed ID: 32861620
[TBL] [Abstract][Full Text] [Related]
9. The Agony and Ecstasy of Prostate Cancer PSMA PET.
Gomella LG
Can J Urol; 2021 Apr; 28(2):10574-10575. PubMed ID: 33872551
[No Abstract] [Full Text] [Related]
10. Management of biochemically recurrent prostate cancer: molecular imaging perspective.
Lorca AM
World J Urol; 2018 Feb; 36(2):321-322. PubMed ID: 29134278
[No Abstract] [Full Text] [Related]
11. FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discov; 2013 Jul; 3(7):OF1. PubMed ID: 23847352
[TBL] [Abstract][Full Text] [Related]
12. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of
Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN
Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423
[TBL] [Abstract][Full Text] [Related]
13. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
14. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
15. [PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection].
Kotzerke J; Böhmer D; Schlomm T; Maurer T; Beer AJ; Schmidberger H
Nuklearmedizin; 2018 Jun; 57(3):69-73. PubMed ID: 29871008
[TBL] [Abstract][Full Text] [Related]
16. FDA approves 11C-choline for PET in prostate cancer.
J Nucl Med; 2012 Dec; 53(12):11N. PubMed ID: 23203247
[No Abstract] [Full Text] [Related]
17. Next-generation imaging in localized high-risk prostate cancer.
Patel DN; Karsh LI; Daskivich TJ
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):585-586. PubMed ID: 33790419
[No Abstract] [Full Text] [Related]
18. PET Imaging for Prostate Cancer.
Savir-Baruch B; Werner RA; Rowe SP; Schuster DM
Radiol Clin North Am; 2021 Sep; 59(5):801-811. PubMed ID: 34392920
[TBL] [Abstract][Full Text] [Related]
19. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
20. Imaging of Prostate Cancer Using Fluciclovine.
Savir-Baruch B; Zanoni L; Schuster DM
PET Clin; 2017 Apr; 12(2):145-157. PubMed ID: 28267449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]